Archie Bleyer, MD
Oregon Health Sciences University
Archie Bleyer, MD, is Clinical Research Professor, Radiation Medicine at Oregon Health Sciences University. He is Chair of the Institutional Research Board, Cascade Healthcare Community; Director of Aflac/CureSearch Adolescent and Young Adult Cancer Research; and founding member of The Livestrong Foundation.
Dr. Bleyer chaired the Children’s Cancer Group for 10 years, then the world's largest pediatric cancer research organization, the Department and Division of Pediatrics at the University of Texas MD Anderson Cancer Center, and Community Oncology in the Department and Division of Medicine at the M.D. Anderson Cancer Center. He was the American Cancer Society Professor of Clinical Oncology and in charge of the cancer curriculum in the University of Washington School of Medicine. During the past three decades,
Dr. Bleyer was awarded research grants totaling more than $75 million as a principal investigator from the National Institutes of Health, the American Cancer Society, and the Leukemia Society of America. His research has been published in more than 300 peer-reviewed articles, chapters, and books. Dr. Bleyer is co-editor of the book, Cancer in Adolescents and Young Adults, now in its second edition. His current personal clinical research is dedicated to adolescents and young adult (AYA) oncology.
Dr. Bleyer earned his medical degree at the University of Rochester, School of Medicine and Dentistry and completed his residency training in Pediatric Medicine at the University of Washington, School of Medicine. He completed his fellowship training at the National Cancer Institute and the University of Washington School of Medicine. Dr. Bleyer is board certified in Pediatrics and Pediatric Hematology/Oncology.
Daniel DeAngelo, MD, PhD
Dana Farber Cancer Institute
Daniel J. DeAngelo, MD, PhD is a Professor of Medicine at Harvard Medical School and the Chief of the Division of Leukemia at Dana-Farber Cancer Institute in Boston, Massachusetts.
Dr. DeAngelo’s clinical research focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes and myeloproliferative disorders including systemic mast cell disorders. He is co-chair of the National Cancer Institute (NCI) leukemia steering committee. He serves on the leukemia core committee for the Alliance Cooperative Group and is principal and co-investigator of several ongoing clinical protocols. He also has an interest in the treatment of young adults with leukemia, particularly acute lymphoblastic leukemia and systemic mastocytosis.
Dr. DeAngelo has authored or coauthored more than 200 original peer-reviewed manuscripts, review articles, and book chapters and has presented his work nationally and internationally.
Dr. DeAngelo earned his MD and PhD in molecular genetics from Albert Einstein College of Medicine of Yeshiva University in Bronx, New York. He completed his internship and residency at Massachusetts General Hospital in Boston and clinical fellowships in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, both in Boston.
Andrew M. Evens, DO, MSc
Rutgers Cancer Institute
Dr. Evens is Associate Director for Clinical Services and
Director, Lymphoma Program, Rutgers Cancer Institute;
Medical Director, Oncology Service Line, RWJBarnabas Health;
Associate Director for Clinical Services; Medical Director of the Oncology Service Line for RWJ Barnabas Health; and Director of the Lymphoma Program. He served as the director of the Cancer Center at Tufts Medical Center in Boston, chief of their division of hematology/oncology, and Professor of Medicine at Tufts University School of Medicine
Dr Evens is an expert in Hodgkin lymphoma, non-Hodgkin lymphoma (all types), chronic lymphocytic leukemia, and autologous hematopoietic stem cell (or bone marrow) transplantation. He manages a translational laboratory studying the biology of lymphoma and to discover new and novel treatments for patients.
Dr. Evens a core member of the Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and a member of several additional clinical and scientific committees for the NIH, NCI, Cancer Therapy Evaluation Program (CTEP), Food and Drug Administration (FDA) and the ECOG/ACRIN group. He is also Vice-Chair of the Lymphoma Committee for the ECOG-ACRIN cancer research group and an elected member of the North American Scientific Advisory Board for the Lymphoma Research Foundation (LRF) and a member of the Board of Trustees for the Leukemia & Lymphoma Society (LLS) New Jersey Chapter.
Dr. Evens completed a prior fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, where he remained as a faculty member altogether for 10 years.
A. Lindsay Frazier, MD
Dana Farber Cancer Institute
Dr. Frazier is Attending Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center. She is Associate Professor of Epidemiology at the Harvard T.H. Chan School of Public Health, and Associate Professor of Pediatrics at Harvard Medical School
Her research focuses on cancer prevention in adolescents, colorectal screening, and germ cell tumors.
Dr. Frazier is the national expert on germ cell tumors in pediatric patients and oversees the care of these patients referred to DFCI. In addition, she is co-chair of two national protocols that opened in 1999 for the treatment of low-risk and high-risk pediatric germ cell tumors and chair of the COG Germ Cell subcommittee in COG Rare Tumors.
Dr Frazier received her MD from Dartmouth Medical School in 1984, followed by a pediatric residency at Children’s Hospital Boston and a pediatric hematology-oncology fellowship at DFCI, where she joined the faculty in 1990. She received an ScM from Harvard School of Public Health in 1993.
Natasha N. Frederick, MD, MPH, MST
Connecticut Children's Medical Center
Dr. Frederick is Director, Comprehensive Fertility and Sexual Health Team in Connecticut Children's Specialty Group. Dr. Frederick is an expert in Oncofertility, in Adolescent and Young Adult (AYA) Oncology, and in Sexual Reproductive Health in AYA oncology patients.
She obtained her MD the University of Vermont College of Medicine and her MPH at the Harvard School of Public Health. Dr. Frederick completed her residency training in Pediatrics at the Hasbro Children’s Hospital/Brown University. She completed Pediatric Hematology and Oncology Fellowship at Boston Children’s Hospital/DFCI and a Faculty Education Fellowship in Medical Humanism and Professionalism at Boston Children’s Hospital. Dr. Frederick is board certified in General Pediatrics and in Pediatric Hematology and Oncology.
David Freyer, DO, MS
Keck School of Medicine, USC
Dr. Freyer is Professor of Clinical Pediatrics and Medicine at the Keck School of Medicine, University of Southern California (USC) and Director of the Survivorship and Supportive Care Program in the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles (CHLA). He is also Director of the LIFE Cancer Survivorship & Transition Service at CHLA and of the LIFE Clinic for Adult Cancer Survivors at the USC Norris Comprehensive Cancer Center (NCCC).
Dr. Freyer oversees clinical cancer survivorship and supportive care services and research, including hematology/oncology-related behavioral health, neuropsychology, and health education. Dr. Freyer’s clinical and research activities are focused principally on cancer survivorship and cancer control, including the recognition, management, and prevention of short-and long-term morbidity of treatment, as well as health care transition for young adult survivors of childhood cancer, adolescent and young adult (AYA) oncology, palliative care, and decision-making at the end of life.
Dr. Freyer is member of the Cancer Control Research Program at the USC member of the Leukemia/Lymphoma Program at CHLA. He is also Chair of the COG AYA Oncology Discipline Committee and on the Cancer Control & Supportive Care and Survivorship & Outcomes Steering Committees
Dr. Freyer earned his medical degree from the Des Moines University College of Osteopathic Medicine and Surgery. He completed a pediatrics residency at Rush University Medical Center and a pediatric hematology/oncology fellowship at the University of Michigan Medical Center/CS Mott Children’s Hospital. He also earned an MS in Clinical Research Design and Statistical Analysis at the University of Michigan School of Public Health.
Lee J. Helman, MD
Dr. Helman is Director of the Osteosarcoma Institute (OSI) and an Adjunct Professor at Children’s Hospital Los Angeles (CHLA). He was head of research at the Cancer and Blood Diseases Research Institute at CHLA until March 2019.
For over thirty years Dr. Helman has cared for pediatric patients with sarcoma. His research has focused on the study of the biology and treatment of rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and pediatric GIST tumors. This research included the study of the pathophysiologic consequences of IGF signaling; identification of the molecular/biochemical determinants of the biology of these sarcomas; and the application of functional genomics to develop novel clinical studies for these sarcomas. He is currently focusing on improving outcomes in osteosarcoma.
Dr. Helman received his medical degree from the University of Maryland School of Medicine Magna Cum Laude. He completed his internship and residency in internal medicine at Barnes Hospital Washington University also serving as chief resident. He began his fellowship training at the NCI where he remained for many years. During his 30 years at NCI, he assumed increasing responsibilities including Chief of Pediatric Oncology, Scientific Director for Clinical Research in the Center for Cancer Research and acting Director of the Center for Cancer Research. He left the NCI to join CHLA in 2017 as Head of Research at the Cancer and Blood Diseases Research Institute.
Michael Isakoff, MD
Connecticut Children's Medical Center
Dr. Isakoff is Clinical Director for the Center for Cancer & Blood Disorders at Connecticut Children’s Medical Center. He is also Medical Director of the Clinical Trials Unit, Director of the Sarcoma Program and Director of the Reid R. Sacco Adolescent and Young Adult Cancer Program.
In 2019 Dr. Isakoff was named by University of Connecticut School of Medicine the Hartford Whalers’ Endowed Chair in Children’s Cancer. He is a member of the Children’s Oncology Group Bone Tumor Steering Committee. Dr. Isakoff's expertise lies in sarcomas in Adolescents and Young Adults.
Dr. Isakoff received his MD at New York University School of Medicine, completed his residency training in Pediatrics at Yale-New Haven Children’s Hospital and completed his fellowship training in Pediatric Hematology/Oncology at Boston Children’s Hospital/DFCI. Dr. Isakoff is board certified in Pediatrics and Pediatric Hematology/Oncology.
Rebecca Johnson, MD
Division of Pediatric Hematology/Oncology Mary Bridge Hospital
Dr. Johnson founded the AYA oncology program at Seattle Children’s Hospital and is building an AYA Program at Mary Bridge Children’s Hospital Multicare Health System, Tacoma, Washington. Her clinical and research interests include patient engagement, cancer epidemiology and unmet needs and barriers to care among AYAs. She co-chairs the National Clinical Trials Network Committee and Chair of the Southwest Oncology Group (SWOG) AYA Committee. She serves on the advisory board of the Children’s Oncology Group (COGS) AYA Committee.
Dr. Johnson earned her medical degree from Sidney Kimmel Medical College, Philadelphia and completed her residency in Pediatrics and Internal Medicine at Milton S. Hershey Medical Center / Pennsylvania State University. Dr. Johnson a Fellowship at Baylor College of Medicine Pediatric Hematology and Oncology; Molecular and Human Genetics; and Pediatric Oncology Clinical Research
Nadine Linendoll, PhD, GNP-BC, MDiv
Tuft Medical Center Cancer Center
Dr. Linendoll is an Assistant Professor of Medicine at Tufts Medical School with over 20 years of experience, first as a bedside nurse and then as oncology nurse practitioner. She is an adult-trained nurse practitioner, initially specializing in neuro-oncology, prior to devoting her time to the Reid R. Sacco AYA Cancer Program. She has a unique education background, which supports her current role. In addition to her doctoral degree from Boston College in nursing, she also received a Master’s of Divinity from Boston University with a special focus on spirituality and healthcare.
Prior to seeing AYAs in clinic, Dr. Linendoll prepares Survivorship Care Plans (including a cumulative treatment summary and long-term follow-up Care Plan) in preparation for each patient’s introductory visit. Following the patients’ initial visit and in all subsequent visits, she oversees their complex care coordination, which spans throughout the greater New England area. One focus of this care has been in onco-fertility and Dr. Linendoll recently completed specialized training through the ECHO program (Enriching Communication Skills for Health Professionals in Oncofertility). Dr. Linendoll is also committed to increasing knowledge and academic scholarship within AYA Survivorship and contributes to health-related quality of life and survivorship-related research.
Susan K Parsons, MD, MRP
Tufts Medical Center
Dr. Parsons’ career has focused on strategies to improve the patient’s experience with healthcare, reduce regimen-related toxicity, and optimize functioning. Her dual clinical interests include the application and evaluation of novel therapies for blood cancers, principally through the National Clinical Trials Network (NCTN) and the care of cancer survivors through her role as medical director of the Reid R. Sacco AYA Cancer Program. Dr. Parsons also oversees the Survivorship Care and the Patient Navigation Programs within the Tufts Cancer Center.
Dr. Parsons and her colleagues address the fiscal impact of critical and chronic illness in studies of total cost of care, cost effectiveness, and more globally, value of intervention.
Since 2007, she has served as a member of the American Society of Blood and Marrow Transplant expert panel on the role of HSCT in the treatment of acute lymphoblastic leukemia in children and adults, and from 2009-2013, served a co-chair of the Health Policy and Psychosocial Working Committee of the Center for International Blood and Marrow Transplant Research. Previously, she served on the Economic Task Force for the Children’s Oncology Group, as member of the Health Services Committee of the American Society of Clinical Oncology, and as a member of the National Cancer Legislation Advisory Committee for which she chaired the HRQL and Quality of Care round tables.
Dr. Parsons has a graduate degree in health economics and planning from Cornell University and a medical degree from Columbia University’s College of Physicians and Surgeons. She completed her pediatrics residency and chief residency at Boston Children’s Hospital (BCH) and a fellowship in pediatric hematology/oncology at BCH/Dana-Farber Cancer Institute.
Mike Roth, MD
MD Anderson Cancer Center
Dr. Roth is Associate Professor of Pediatrics at The University of Texas MD Anderson Cancer Center. He is Director of the Childhood Cancer Survivorship Program and Co-director of the AYA Program.
Dr. Roth specializes in caring for children and adolescents with leukemia and lymphoma. Dr. Roth’s clinical research focuses on improving outcomes for adolescents and young adults (AYAs) with cancer.
Dr. Roth is Chair of Children’s Oncology Group AYA Oncology Discipline Committee and leads the AYA Responsible Investigator Network.
Dr. Roth graduated from New York University School of Medicine and completed a Pediatrics residency and a Pediatric Hematology/Oncology fellowship at the Albert Einstein College of Medicine
Stuart Siegel, MD
Pediatric Hematology-Oncology Specialist, Ventura, CA
Dr. Siegel is a retired pediatric hematologist-oncologist and university professor who is currently involved in leadership roles in several regional and national non-profit organizations dealing with children's health. He consults internationally pediatric health and hospital development and in the programmatic development in pediatric and young adult oncology. Dr. Siegel was Chief of the Division of Hematology/Oncology Children’s Hospital Los Angeles for 35 years and the founding director of the the Children’s Center for Cancer & Blood Diseases. He was Professor and Head of the Division of Hematology-Oncology Department of Pediatrics, Keck School of Medicine of University of Southern California. Dr. Siegel is the founder and president of Southern California Children's Cancer Services, the predecessor to Ronald McDonald House Charities of Southern California, and is a member of the National Board of Ronald McDonald House Charities.
Dr. Siegel recently shifted his focus to international medicine and remains a leader in supportive care and research in pediatric oncology, with a special focus on neuroblastoma, non-Hodgkin lymphoma, Ewing Sarcoma, acute lymphoblastic leukemia and brain tumors. From developing the first pediatric protective environment in 1971 for children undergoing intensive chemotherapy, to pioneering current efforts to develop academic and clinical care programs nationally and locally for adolescents and young adults with cancer, Dr. Siegel’s contributions have revolutionized the field of pediatric oncology.
Dr. Siegel received his medical degree from Boston University School of Medicine. He completed his and pediatric training at the University of Minnesota and his pediatric oncology training at the National Cancer Institute.
Kathy Warren, MD
Dana Farber Cancer Institute
Dr. Warren is an internationally recognized expert in pediatric neuro-oncology. She was appointed Clinical Director of Pediatric Neuro-Oncology at Dana-Farber/Boston Children's in 2019 and was previously Senior Investigator and head of the Neuro-Oncology Section in the Pediatric Oncology branch of the National Cancer Institute where she worked for more than 25 years. Her major focus is developing new therapeutics to improve the outcome and quality of life for children with CNS tumors. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery. Her clinical trials have led the field in exploring new approaches for the treatment of children with these diseases. Dr. Warren has extensive experience in pharmacology, neuro-imaging, and clinical trial design and incorporates each of these into her research. She has led a number of clinical trials, including single institution, multi-institution, national consortium, and international trials.
Dr. Warren currently serves as the chair of RAPNO (Response Assessment in Pediatric Neuro-Oncology), a member of the NCI Brain Malignancy Steering Committee, NCI Clinical Trials, and Translational Research Advisory Committee Ad hoc Working Group on Glioblastoma, and is a steering committee member for the DIPG Registry. She has served on numerous national and international scientific committees and advisory boards.
A. Lindsay Frazier, MD
Dana Farber Cancer Institute
Dr. Frazier concentrates on germ cell tumors, while her epidemiologic research primarily focuses on colorectal cancer screening and prevention.
Dr Fazier received her MD from Dartmouth Medical School in 1984, followed by a pediatric residency at Children’s Hospital Boston and a pediatric hematology-oncology fellowship at DFCI, where she joined the faculty in 1990. She received an ScM from Harvard School of Public Health in 1993.